RxDoctor Payments Data

Michael McCormack

Pulmonary Disease · Knoxville, TNNPI 1114934676

Payments from drug & device makers

$2,677in general payments, 2019–2025

Across 159 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$415
  • AstraZeneca$336
  • Boehringer Ingelheim$327
  • Insmed, Inc.$283
  • Actelion Pharmaceuticals US, Inc.$263
  • United Therapeutics Corporation$202
  • plus $851 from 15 others

What the payments were for

  • Food & beverage$2,60297%
  • Education$753%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,677 in reported general payments places this provider in the 40th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee

Most prescribed under Part D

DrugClaimsCost to plans & patients
ColistimethateColistin (Colistimethate Na)11$1,180

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →